HCM Earnings Date: Mar 4, 2027 (Estimated) — HUTCHMED (China) Limited American Depositary Shares
XNAS
Updated
When is HCM's next earnings date?
HUTCHMED (China) Limited American Depositary Shares (HCM) is expected to report FY 2026 earnings on Thursday, March 4, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.21 on revenue of $623.5M.
How did HCM do in its last earnings report?
In its most recent report on Jul 30, 2026 (H1 2026), HUTCHMED (China) Limited American Depositary Shares posted EPS of $0.09 versus the $0.14 estimate, a miss of 37.9%. Revenue was $278.3M against a $304.2M estimate. The stock's 1-day post-earnings move was -5.4%.
How much does HCM stock move after earnings?
HCM beat EPS estimates in 3 of its last 4 reported quarters. Over the last 7 reports the stock moved an average of 5.9% (up or down) in the day after earnings.
About HUTCHMED (China) Limited American Depositary Shares
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | H1 2026 | 0.14 | 0.09 | -37.93% | $278.3M | ❌ Miss | -5.44% | +1.40% | +9.00% |
| 2026-03-05 | FY 2025 | 1.43 | 2.62 | +83.22% | $548.5M | ✅ Beat | +1.50% | +6.78% | +13.01% |
| 2025-08-07 | H1 2025 | — | 2.61 | — | $277.7M | — | -9.01% | -10.74% | -10.91% |
| 2025-03-19 | FY 2024 | — | 0.22 | — | $630.2M | ✅ Beat | +8.23% | -2.21% | -8.09% |
| 2024-07-31 | H1 2024 | — | 0.15 | — | $305.7M | — | +8.00% | +12.33% | -3.89% |
| 2024-02-28 | FY 2023 | — | 0.58 | — | $838.0M | — | -4.88% | -13.51% | +5.38% |
| 2023-07-31 | H1 2023 | — | 0.97 | — | $532.9M | — | -4.42% | +11.96% | +0.54% |
| 2022-08-01 | -1.02 | -0.95 | — | $202.0M | ✅ Beat | — | — | — |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q4 FY23 · $121.4M total
| Segment | Share | Revenue | YoY | Q2 FY20 | Q2 FY21 | Q2 FY22 | Q2 FY23 |
|---|---|---|---|---|---|---|---|
| Collaboration Research And Development | 42.6% | $51.7M | — | $7.5M | $4.8M | $12.3M | $28.7M |
| Other Collaboration Licensing Revenue | 23.7% | $28.8M | — | — | — | $15.0M | $250.1M |
| Commercialization Services | 19.1% | $23.2M | — | — | $15.0M | $21.6M | $25.4M |
| Other Collaboration Royalties Revenue | 14.4% | $17.5M | — | $2.0M | $5.8M | $14.3M | $15.0M |
| Research And Development Services | 0.2% | $235K | — | $240K | $261K | $263K | $246K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.